Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Metastatic Colorectal CancerMicrosatellite Stable Colorectal CarcinomaRAS MutationCadonilimab

Interventions

DRUG

Cadonilimab + bevacizumab + FOLFOX

Trial Locations (1)

RECRUITING

Zhongshan hosptial, Fudan University, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER